A golden year of innovative kidney disease therapeutics

IF 28.6 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Nephrology Pub Date : 2025-01-03 DOI:10.1038/s41581-024-00916-z

Monica Suet Ying Ng, Carmel M. Hawley

引用次数: 0

Abstract

In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist, a soluble guanylate cyclase activator and an off-the-shelf, virus-specific T cell therapy. These advances herald new hope for people with kidney disease.

Abstract Image

查看原文本刊更多论文

创新肾脏疾病治疗的黄金年

2024年，大量新的肾脏疾病治疗策略进入临床试验阶段，包括RNA干扰治疗、胰高血糖素样肽1受体激动剂、可溶性鸟苷酸环化酶激活剂和现成的病毒特异性T细胞治疗。这些进展为肾病患者带来了新的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Nephrology 医学-泌尿学与肾脏学

CiteScore

39.00

自引率

1.20%

发文量

127

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Nephrology aims to be the premier source of reviews and commentaries for the scientific communities it serves. It strives to publish authoritative, accessible articles. Articles are enhanced with clearly understandable figures, tables, and other display items. Nature Reviews Nephrology publishes Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements. The content is relevant to nephrologists and basic science researchers. The broad scope of the journal ensures that the work reaches the widest possible audience.